Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery.
Prophylactic administration of platelet concentrates to patients undergoing their first cardiopulmonary bypass operation (coronary artery bypass grafting or uncomplicated valve replacement) was evaluated in a controlled randomized study of 28 patients. Four units of platelet concentrates administered at the end of bypass prevented prolongation of the bleeding time seen in patients not receiving platelets. However, chest tube blood loss, transfusion requirements, and clinical outcome were not improved. Moreover, thrombocytopenia and prolongation of bleeding time did not correlate with blood loss or transfusion needs. Mild thrombocytopenia (to 58,000 platelets per microliter) and transient platelet dysfunction after bypass do not require administration of platelet concentrates, and prophylactic use of this blood component in the surgical setting of bypass is not indicated.
D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass; D002986:Clinical Trials as Topic; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D017713:Platelet Transfusion; D011183:Postoperative Complications / Q000517:prevention & control; D011897:Random Allocation; D013896:Thoracic Diseases / Q000517:prevention & control; D013921:Thrombocytopenia / Q000517:prevention & control*